Table 1.
Characteristics of the study population (mean ± SEM)
| Fracture N=68 | Non-fracture N=101 | P-value | |
|---|---|---|---|
| Age (years) | 69 ± 1 | 68 ± 1 | 0.30 |
| Race % Caucasian | 81% | 76% | 0.93 |
| % African American | 3% | 5% | |
| % Hispanic | 15% | 17% | |
| % Other | 1% | 2% | |
| Height (cm) | 160 ± 1 | 161 ± 1 | 0.36 |
| Weight (kg) | 67 ± 2 | 68 ± 2 | 0.60 |
| Years since menopause | 20 ± 1 | 18 ± 1 | 0.34 |
| Oophorectomy (%) | 18% | 18% | 0.99 |
| Family history of osteoporosis (%) | 49% | 44% | 0.63 |
| Family history of fracture (%) | 38% | 36% | 0.87 |
| Tobacco use –Pack years | 22 ± 5 | 21 ± 3 | 0.85 |
| Never (%) | 50% | 44% | |
| Former (%) | 50% | 54% | |
| Current (%) | 0% | 1% | |
| Alcohol use (beverages per day) | 1 ± 0 | 1 ± 0 | 0.99 |
| Medication Use | |||
| Calcium supplements – total daily dose (mg) | 608 ± 78 | 612 ± 60 | 0.97 |
| Vitamin D supplements – total daily dose (IU) | 568 ± 78 | 797 ± 135 | 0.19 |
| Hormone replacement therapy – Past (%) | 42% | 46% | 0.87 |
| Current (%) | 3% | 6% | 0.67 |
| Bisphosphonates - Past (%) | 6% | 5% | 0.99 |
| Current (%) | 4% | 1% | 0.46 |
| Raloxifene (%) | 6% | 2% | 0.37 |
| Thyroxine (%) | 8% | 22% | 0.02 |